Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Releases Early Safety Data Linking Prilosec And Nexium To Cardiac Problems

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is reviewing safety data on Prilosec and Nexium but is not recommending any changes in prescribing practices.

You may also be interested in...



FDA Finds Statins Not Linked To ALS; When Can A False Alarm Be Turned Off?

FDA's determination that statins do not increase the incidence of amyotrophic lateral sclerosis suggests that agency will continue to rely on data from placebo controlled trials to address concerns raised in post-marketing reports

FDA Finds Statins Not Linked To ALS; When Can A False Alarm Be Turned Off?

FDA's determination that statins do not increase the incidence of amyotrophic lateral sclerosis suggests that agency will continue to rely on data from placebo controlled trials to address concerns raised in post-marketing reports

Prilosec Approved For GERD In Infants

Approval comes weeks after Nexium gained clearance in patients 1 to 11.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel